Drug intelligence / Profile preview

AmnioVisc

Development stage: Unknown
Lead developer: Lattice Biologics
Modality: Adoptive Cell Transfer → Cell Therapies, Other Cell Types → Cell Therapies, Stem Cell Therapies → Cell Therapies
Administration: Intra-articular Injection

Overview

AmnioVisc is a minimally processed amniotic fluid allograft developed by Lattice Biologics. It is designed as a viscosupplement for the treatment of osteoarthritis joint pain in various joints, including the knee, elbow, shoulder, wrist, foot, ankle, neck, and spine. The product leverages the natural anti-inflammatory and regenerative properties of amniotic fluid to provide pain relief and promote tissue repair. It is distributed in the US through partnerships with OsteoArthritis Centers of America, Resilience, and Cryoport, and is noted to be covered by Medicare protocols for its intended use.

Brand names: AmnioVisc

Beyond the preview

Go deeper on AmnioVisc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmnioVisc.

Explore the full profile